-
The woman in your exam room says she is experiencing a painful, burning sensation when urinating, and reports increased vaginal discharge. The test is positive for gonorrhea. What's your next move?
-
Recent research findings indicate that young women who use the commonly used epilepsy drug phenytoin for one year showed significant bone loss compared to women taking other epilepsy drugs.
-
If your clinical practice includes treatment of perimenopausal women, the subject of hot flashes is familiar territory for you. In a 2002 national survey of menopausal women, hot flashes (70%) led the top four reasons for seeking medical attention, followed by night sweats (68%), mood disturbances (50%), and sleep disturbances (49%).
-
As a women's health care provider, you are familiar with interstitial cystitis (IC) and painful bladder syndrome (PBS). It is estimated that at least 1 million Americans suffer from IC/PBS, most of them women.
-
-
Pioglitazone and heart disease; ARBs manufacturers spend millions to show the non-inferiority of their products compared to less expensive, generic ACE inhibitors; some athletes turn to growth hormone because it is difficult to detect; FDA Actions
-
Most of us dread the chief complaint of weakness. This nonspecific symptom engenders a differential that ranges from malingering to fatal, from psychiatric to cancer. The finding of demonstrable muscle weakness helps, but then leads to a confusing set of relatively rare diagnoses.
-
-
Lifestyle changes such as improving diet and exercise are always the first important approach for the treatment of hyperlipidemia however, if the target LDL-C level is not achieved using statins and niacin, fibrates, and/or resins, at this time, ezetimibe should definitely be utilized to achieve these target goals if there are no specific contraindications to the use of the drug in each individual patient.
-
For those women who were randomized to estrogen plus progesterone in the Women's Health Initiative Trial, the increased risk of breast cancer has persisted since stopping the replacement therapy, but the increased risk of cardiovascular events has returned to that of the placebo group.
